Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target

Zacary P. Germon; Jonathan R. Sillar; Abdul Mannan; Ryan Duchatel; Heather C. Murray; Alicia Douglas; Honggang Huang; Kristy McCarthy; Frank Alvaro; Janis Chamberlain; Andrew Wei; Anoop K. Enjeti; Martin R. Larsen; Nicole M. Verrills; Matthew D. Dun

doi:10.1111/ajco.13472

Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target

Zacary P. Germon, Jonathan R. Sillar, Abdul Mannan, Ryan Duchatel, Heather C. Murray, Alicia Douglas, Honggang Huang, Kristy McCarthy, Frank Alvaro, Janis Chamberlain, Andrew Wei, Anoop K. Enjeti, Martin R. Larsen, Nicole M. Verrills, Matthew D. Dun

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	RF8
Journal	Asia Pacific Journal of Clinical Oncology
Volume	16
Issue number	Suppl. 6
Pages (from-to)	25-26
ISSN	1743-7555
DOIs	https://doi.org/10.1111/ajco.13472
Publication status	Published - 3. Nov 2020
Event	2020 Hunter Cancer Research Symposium - Newcastle, Australia Duration: 6. Nov 2020 → …

Conference

Conference	2020 Hunter Cancer Research Symposium
Country/Territory	Australia
City	Newcastle
Period	06/11/2020 → …

Documents & Links

10.1111/ajco.13472

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Germon, Z. P., Sillar, J. R., Mannan, A., Duchatel, R., Murray, H. C., Douglas, A., Huang, H., McCarthy, K., Alvaro, F., Chamberlain, J., Wei, A., Enjeti, A. K., Larsen, M. R., Verrills, N. M., & Dun, M. D. (2020). Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target. Asia Pacific Journal of Clinical Oncology, 16(Suppl. 6), 25-26. Article RF8. https://doi.org/10.1111/ajco.13472

@article{e897f34885f84bf2884e7351ad00036d,

title = "Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target",

author = "Germon, {Zacary P.} and Sillar, {Jonathan R.} and Abdul Mannan and Ryan Duchatel and Murray, {Heather C.} and Alicia Douglas and Honggang Huang and Kristy McCarthy and Frank Alvaro and Janis Chamberlain and Andrew Wei and Enjeti, {Anoop K.} and Larsen, {Martin R.} and Verrills, {Nicole M.} and Dun, {Matthew D.}",

year = "2020",

month = nov,

day = "3",

doi = "10.1111/ajco.13472",

language = "English",

volume = "16",

pages = "25--26",

journal = "Asia Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley",

number = "Suppl. 6",

note = "2020 Hunter Cancer Research Symposium ; Conference date: 06-11-2020",

}

Germon, ZP, Sillar, JR, Mannan, A, Duchatel, R, Murray, HC, Douglas, A, Huang, H, McCarthy, K, Alvaro, F, Chamberlain, J, Wei, A, Enjeti, AK, Larsen, MR, Verrills, NM & Dun, MD 2020, 'Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target', Asia Pacific Journal of Clinical Oncology, vol. 16, no. Suppl. 6, RF8, pp. 25-26. https://doi.org/10.1111/ajco.13472

Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target. / Germon, Zacary P.; Sillar, Jonathan R.; Mannan, Abdul et al.
In: Asia Pacific Journal of Clinical Oncology, Vol. 16, No. Suppl. 6, RF8, 03.11.2020, p. 25-26.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target

AU - Germon, Zacary P.

AU - Sillar, Jonathan R.

AU - Mannan, Abdul

AU - Duchatel, Ryan

AU - Murray, Heather C.

AU - Douglas, Alicia

AU - Huang, Honggang

AU - McCarthy, Kristy

AU - Alvaro, Frank

AU - Chamberlain, Janis

AU - Wei, Andrew

AU - Enjeti, Anoop K.

AU - Larsen, Martin R.

AU - Verrills, Nicole M.

AU - Dun, Matthew D.

PY - 2020/11/3

Y1 - 2020/11/3

U2 - 10.1111/ajco.13472

DO - 10.1111/ajco.13472

M3 - Conference abstract in journal

SN - 1743-7555

VL - 16

SP - 25

EP - 26

JO - Asia Pacific Journal of Clinical Oncology

JF - Asia Pacific Journal of Clinical Oncology

IS - Suppl. 6

M1 - RF8

T2 - 2020 Hunter Cancer Research Symposium

Y2 - 6 November 2020

ER -